Instigation of endothelial Nlrp3 inflammasome by adipokine visfatin promotes inter-endothelial junction disruption: Role of HMGB1

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 12, 2015, Pages 2715-2727

  Chen, Yang ^a   Pitzer, Ashley L ^a   Li, Xiang ^a,b   Li, Pin Lan ^a   Wang, Lei ^a   Zhang, Yang ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Endothelium; Nlrp3 inflammasome; Obesity; Tight junction proteins; Visfatin

Indexed keywords

CRYOPYRIN; HIGH MOBILITY GROUP B1 PROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ADIPOCYTOKINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, MOUSE; INFLAMMASOME; NLRP3 PROTEIN, MOUSE; TIGHT JUNCTION PROTEIN; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CELL ADHESION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORONARY ARTERY; CORRELATION COEFFICIENT; DENSITOMETRY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; LIPID DIET; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL JUNCTION; CELL LINE; CELL MOTION; CORONARY BLOOD VESSEL; DRUG EFFECTS; GENETICS; IMMUNOBLOTTING; KNOCKOUT MOUSE; METABOLISM;

ADIPOKINES; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; CELL LINE; CELL MOVEMENT; CORONARY VESSELS; DIET, HIGH-FAT; ENDOTHELIAL CELLS; HMGB1 PROTEIN; IMMUNOBLOTTING; INFLAMMASOMES; INTERCELLULAR JUNCTIONS; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RNA INTERFERENCE; TIGHT JUNCTION PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 84955180839     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12657     Document Type: Article

References (67)

1. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67: 968-77.
2. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004; 350: 2362-74.
3. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002; 346: 591-602.
4. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14: 1431-7.
5. Bailey SD, Loredo-Osti JC, Lepage P, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes. 2006; 55: 2896-902.
6. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006; 91: 295-9.
7. Spiroglou SG, Kostopoulos CG, Varakis JN, et al. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb. 2010; 17: 115-30.
8. Shively CA, Register TC, Clarkson TB. Social stress, visceral obesity, and coronary artery atherosclerosis: product of a primate adaptation. Am J Primatol. 2009; 71: 742-51.
9. Boini KM, Zhang C, Xia M, et al. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther. 2010; 334: 839-46.
10. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010; 10: 210-5.
11. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10: 826-37.
12. Menu P, Pellegrin M, Aubert JF, et al. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2011; 2: e137.
13. Abais JM, Zhang C, Xia M, et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid Redox Signal. 2013; 18: 1537-48.
14. Zhang C, Boini KM, Xia M, et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension. 2012; 60: 154-62.
15. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010; 11: 136-40.
16. Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004; 430: 213-8.
17. Lamkanfi M, Malireddi RK, Kanneganti TD. Fungal zymosan and mannan activate the cryopyrin inflammasome. J Biol Chem. 2009; 284: 20574-81.
18. Kanneganti TD, Body-Malapel M, Amer A, et al. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem. 2006; 281: 36560-8.
19. Imaeda AB, Watanabe A, Sohail MA, et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest. 2009; 119: 305-14.
20. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237-41.
21. Xia M, Boini KM, Abais JM, et al. Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. Am J Pathol. 2014; 184: 1617-28.
22. Vandenbroucke E, Mehta D, Minshall R, et al. Regulation of endothelial junctional permeability. Ann N Y Acad Sci. 2008; 1123: 134-45.
23. Nyqvist D, Giampietro C, Dejana E. Deciphering the functional role of endothelial junctions by using in vivo models. EMBO Rep. 2008; 9: 742-7.
24. Giehl K, Menke A. Microenvironmental regulation of E-cadherin-mediated adherens junctions. Front Biosci. 2008; 13: 3975-85.
25. Cereijido M, Contreras RG, Shoshani L, et al. Tight junction and polarity interaction in the transporting epithelial phenotype. Biochim Biophys Acta. 2008; 1778: 770-93.
26. Hernandez S, Chavez Munguia B, Gonzalez-Mariscal L. ZO-2 silencing in epithelial cells perturbs the gate and fence function of tight junctions and leads to an atypical monolayer architecture. Exp Cell Res. 2007; 313: 1533-47.
27. Balda MS, Matter K. Tight junctions and the regulation of gene expression. Biochim Biophys Acta. 2009; 1788: 761-7.
28. Dejana E, Corada M, Lampugnani MG. Endothelial cell-to-cell junctions. FASEB J. 1995; 9: 910-8.
29. Runkle EA, Mu D. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett. 2013; 337: 41-8.
30. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009; 11: 615-28.
31. Boini KM, Xia M, Abais JM, et al. Activation of inflammasomes in podocyte injury of mice on the high fat diet: effects of ASC gene deletion and silencing. Biochim Biophys Acta. 2014; 1843: 836-45.
32. Chen Y, Li X, Boini KM, et al. Endothelial Nlrp3 inflammasome activation associated with lysosomal destabilization during coronary arteritis. Biochim Biophys Acta. 2015; 1853: 396-408.
33. Zhang Y, Li X, Carpinteiro A, et al. Kinase suppressor of Ras-1 protects against pulmonary Pseudomonas aeruginosa infections. Nat Med. 2011; 17: 341-6.
34. Li X, Gulbins E, Zhang Y. Role of kinase suppressor of ras-1 in lipopolysaccharide-induced acute lung injury. Cell Physiol Biochem. 2012; 30: 905-14.
35. Wei YM, Li X, Xu M, et al. Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes. Cell Physiol Biochem. 2013; 31: 925-37.
36. Wei YM, Li X, Xiong J, et al. Attenuation by statins of membrane raft-redox signaling in coronary arterial endothelium. J Pharmacol Exp Ther. 2013; 345: 170-9.
37. Li X, Xu M, Pitzer AL, et al. Control of autophagy maturation by acid sphingomyelinase in mouse coronary arterial smooth muscle cells: protective role in atherosclerosis. J Mol Med. 2014; 92: 473-85.
38. Amstad PA, Yu G, Johnson GL, et al. Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors. Biotechniques. 2001; 31: 608-10, 12, 14, passim.
39. Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 2012; 488: 670-4.
40. Huang W, Liu Y, Li L, et al. HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways. Inflammation. 2012; 35: 350-62.
41. Rabadi MM, Kuo MC, Ghaly T, et al. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiol Renal Physiol. 2012; 302: F730-41.
42. Yang H, Lundback P, Ottosson L, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med. 2012; 18: 250-9.
43. Xia M, Zhang C, Boini KM, et al. Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin. Cardiovasc Res. 2011; 89: 401-9.
44. Muhammad S, Barakat W, Stoyanov S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci. 2008; 28: 12023-31.
45. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006; 26: 174-9.
46. Bauer EM, Shapiro R, Billiar TR, et al. High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). J Biol Chem. 2013; 288: 1365-73.
47. Simionescu N, Simionescu M, Palade GE. Open junctions in the endothelium of the postcapillary venules of the diaphragm. J Cell Biol. 1978; 79: 27-44.
48. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004; 84: 869-901.
49. Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell. 2013; 26: 441-54.
50. Li X, Zhang Y, Xia M, et al. Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration: implication of a novel role of inflammasome in atherogenesis. PLoS One. 2014; 9: e87552.
51. Sappington PL, Yang R, Yang H, et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology. 2002; 123: 790-802.
52. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006; 290: C917-24.
53. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005; 61: 1-9.
54. Rouhiainen A, Kuja-Panula J, Wilkman E, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood. 2004; 104: 1174-82.
55. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003; 254: 375-85.
56. Wolfson RK, Chiang ET, Garcia JG. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res. 2011; 81: 189-97.
57. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000; 406: 782-7.
58. Lv B, Wang H, Tang Y, et al. High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost. 2009; 102: 352-9.
59. Franchi L, Eigenbrod T, Munoz-Planillo R, et al. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009; 10: 241-7.
60. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 2005; 26: 447-54.
61. Abais JM, Xia M, Zhang Y, et al. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid Redox Signal. 2015; 22: 1111-29.
62. Kepp O, Galluzzi L, Zitvogel L, et al. Pyroptosis - a cell death modality of its kind? Eur J Immunol. 2010; 40: 627-30.
63. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011; 32: 373-9.
64. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011; 11: 213-20.
65. Misawa T, Takahama M, Kozaki T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013; 14: 454-60.
66. Nicolson GL, Ash ME. Lipid replacement therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function. Biochim Biophys Acta. 2014; 1838: 1657-79.
67. Gattorno M, Martini A. Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence. Arthritis Rheum. 2013; 65: 1137-47.